DalsnaFinance

Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026

Markets PR Newswire By PR Newswire 19 Jun 2026 13:00 1 min read
Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026

SAN DIEGO, June 19, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, and MOTE Therapeutics, a preclinical-stage biotech company developing a novel targeted LNP delivery platform and in vivo CAR-T therapies, today...

SAN DIEGO, June 19, 2026 /PRNewswire/ -- Fapon Biopharma, a clinical-stage biotech company innovating therapeutic antibodies and fusion proteins, and MOTE Therapeutics, a preclinical-stage biotech company developing a novel targeted LNP delivery platform and in vivo CAR-T therapies, today...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.